Skip to main content
Erschienen in: Breast Cancer 2/2011

01.04.2011 | Special Feature

Preoperative therapy: recent findings

verfasst von: Takayuki Kinoshita

Erschienen in: Breast Cancer | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Preoperative systemic therapy (PST) is the standard treatment for locally advanced breast cancer and a standard option for primary operable breast cancer. PST for breast cancer is as effective as postoperative adjuvant therapy, which permits more lumpectomies and can be used to study breast cancer biology. For locally advanced breast cancer patients, the primary aim of PST is to improve surgical option. For operable breast cancer patients, the primary aim of PST is to obtain freedom from disease. Because of recent advances in treatment and our understanding of the disease, we summarized the current consensus on the adoption and benefits of PST, especially for operable breast cancer patients.
Literatur
1.
Zurück zum Zitat Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;8:2672–85. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;8:2672–85.
2.
Zurück zum Zitat Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMed Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMed
3.
Zurück zum Zitat Van der Huge JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37. Van der Huge JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37.
4.
Zurück zum Zitat Kaufmann M, Hortobagi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendation from an international expert panel on the use of neoadjuvant systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.PubMedCrossRef Kaufmann M, Hortobagi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendation from an international expert panel on the use of neoadjuvant systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.PubMedCrossRef
5.
Zurück zum Zitat Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;15:1456–66.CrossRef Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;15:1456–66.CrossRef
6.
Zurück zum Zitat Semiglazov, VF, Semiglazov, VV, Berstein LM (2003) In: Proceedings of SABC (abstract). Semiglazov, VF, Semiglazov, VV, Berstein LM (2003) In: Proceedings of SABC (abstract).
Metadaten
Titel
Preoperative therapy: recent findings
verfasst von
Takayuki Kinoshita
Publikationsdatum
01.04.2011
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2011
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0227-4

Weitere Artikel der Ausgabe 2/2011

Breast Cancer 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.